Abstract: Aspirin is widely used internationally for a variety of indications, with the most prominent one being that of cardiovascular disease. However, aspirin has also been proposed as a treatment option in a diverse range of conditions such as diabetes mellitus, cancer prevention, and obstetrics. In our overview, we critically appraise the current evidence from recent systematic reviews and meta-analyses covering the benefits of aspirin across these conditions. We also look at evidence that some patients may not derive benefit due to the concept of aspirin resistance. Aspirin is also associated with the potential for significant harm, principally from haemorrhagic adverse events. We critically appraise the threat of haemorrhagic complications, and weigh up these risks against that of any potential benefit.

Keywords: aspirin; efficacy; adverse events

1. Introduction

The use of salicylic acid in medicine stretches back to antiquity. Early medicines containing salicylic acid were derived from willow bark and other salicylate-rich plants. These formulations were recognized for their antipyretic, analgesic and anti-inflammatory properties, but were also found to have gastrointestinal side effects. The modern form, aspirin or acetylsalicylic acid, is the acetylated version of the natural product and was developed with the aim of improving the tolerability of the drug. More recently, research into the mechanism of action of aspirin led to the discovery that it
inhibited the production of prostaglandins. This has resulted in a multitude of new applications for aspirin encompassing conditions such as cardiovascular disease, pre-eclampsia, and cancer prevention. The increasing numbers of people being exposed to aspirin has also led to the awareness of the significant potential harm arising from the adverse haemorrhagic effects of aspirin (e.g. gastrointestinal and intracranial bleeds). Hence there is need to critically consider the evidence behind the therapeutic indications for aspirin, and decide whether the anticipated benefit outweighs the potential for harm.

In patients with high risk of vascular disease, antiplatelet therapy has been shown to reduce vascular events by about a quarter [1,2]. The benefits of aspirin treatment in secondary prevention seem to outweigh the risks, but this is much less clear for primary prevention in healthy individuals where the risk of thrombotic cardiac events is somewhat lower [3]. A number of current guidelines recommend the use of aspirin in primary prevention, but do not fully consider the risk of bleeding [4–6]. Aspirin is also widely used in certain subgroups of patients, e.g. patients with diabetes mellitus, and those with peripheral vascular disease, where the precise benefits have not been fully clarified.

Moreover, there has been recent concern that some patients with cardiovascular disease are aspirin resistant and do not benefit from normally recommended dose of aspirin therapy and it is unclear how to identify such patients [7–13]. It is not understood why patients become aspirin resistant and it may related to inadequate dosages, poor compliance, reduced ability to absorb aspirin or genetic predisposition [14–19]. The validity of platelet function testing, and its correlation with cardiovascular event, remain a hotly debated topic.

Aspirin may also have a role in obstetrics, particularly in conditions such as pre-eclampsia where vascular dysfunction in the placental beds is a potential aetiological factor. A systematic review from some years back suggests that aspirin has beneficial effects on important outcomes, with reductions in the relative risks of pre-eclampsia, preterm birth and baby death [20]. This remains a controversial area though, as early trials have shown conflicting results compared to more recent larger studies [21–26].

Inhibition of cyclooxygenase may have a useful role in suppression of neoplasia, as demonstrated by epidemiological studies and clinical trials that have reported reduced risk of colorectal cancer with non-steroidal anti-inflammatory agents [27,28]. There appears to be a potential association between aspirin use and a reduction in the risk of colorectal cancer [28–30], and colorectal adenomas [27, 31–33]. The benefits of aspirin may also extend to other tumours such as breast cancer [34,35], and the evidence in these areas certainly merits further detailed scrutiny. Many clinical studies have evaluated the association between non-steroidal anti-inflammatory use and breast cancer and these studies have reported inconsistent results [36–45]. Two meta-analyses have pooled the data and both have shown similar a risk reduction for use of NSAIDS and aspirin compared to control. These reviews have not considered both the effect of a dose-response relationship that considers both frequency and duration of use.

While the risks of gastrointestinal and cerebral haemorrhage with aspirin have already been studied in detail [46,47], the problems with aspirin may manifest elsewhere. The large number of patients on aspirin creates a conundrum for clinicians who are performing surgery or interventional vascular procedures on such patients, given concerns about increased risk of post-procedural bleeding from wound sites. Should aspirin be stopped prior to interventional procedures, bearing in mind the possibility of a thrombotic events? [48]. Some studies suggest that continued aspirin therapy during the
operation is associated with increased risk of blood transfusion during the surgery, while other studies have suggested the contrary, including survival benefit associated with continued use of aspirin [49–55].

The aim of this review is to update and critically appraise the evidence from recent meta-analyses (published within the past three years) covering the common and potential applications of aspirin and evaluating the benefits and harms of treatment.

2. Experimental Methods

Systematic reviews and meta-analyses that included adult patients who had aspirin therapy as a main focus were included. There was no restriction on the indication for aspirin therapy but the meta-analysis must have reported either efficacy outcomes and/or adverse events outcomes. Studies were excluded if there were more recent meta-analyses reviewing the same topic.

Recent reviews were identified by searching Medline from January 2007 until March 2010. The following terms and keywords were used [(aspirin) AND systematic[sb]]. The search was limited to meta-analyses published in English and human studies.

The studies retrieved were checked independently by two reviewers (CSK and YKL) and relevant reviews were selected according to the stated inclusion and exclusion criteria. Disagreements were resolved by consensus.

Data was extracted by CSK and checked by YKL. The characteristics of the participants included in each meta-analysis were extracted, including the total number of patients, mean age, percentage of females, the types of studies included, the main results and the validity of the primary studies based on the reviewer’s assessment.

Where available, number needed to treat for benefit (NNTB) and harm (NNTH) were extracted directly from the meta-analyses of controlled trials. If not, we extracted the event rates (%) for the pooled control and aspirin arms in order to illustrate the absolute risk reduction/increases with aspirin. The NNTB and NNTH with 95% confidence intervals (95% CI) for selected key outcomes was then calculated by applying the relative risk to the control event rate using the Visual Rx website. (http://www.nntonline.net/visualrx/)

3. Results and Discussion

We identified 21 potentially relevant meta-analyses articles eligible for our overview. Of these, nine were excluded because there were more recent reviews with additional studies. Of the 12 relevant analyses, the key ones with quantitative data on absolute and relative risk estimates are shown in Table 1. Study selection is shown in Figure 1. The characteristics of the trials included in the meta-analyses of this review are shown in Table 1, and the NNT for key outcomes are summarized in Table 2.
### Table 1. Characteristics of key meta-analyses in current review.

| Study           | Trials and design | Participants | Outcomes | Findings                                                                 | Quality                                                                                       |
|-----------------|-------------------|--------------|----------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Alghamdi 2007 [62] | 10 studies; 5 trials, 5 cohort studies | 1,748 participants; 913 aspirin group, 835 control group | Risk of bleeding in coronary artery bypass graft patients | Aspirin use was associated with increase in blood loss, red cell and fresh frozen plasma transfusion, but not platelets or reexploration. | Results were limited because of heterogeneity and poor methodological quality |
| Askie 2007 [58]   | 31 trials         | 32,217 women and 32,819 babies | Risk of pre-eclampsia and pregnancy outcomes | Aspirin associated with reduced risk of pre-eclampsia, preterm delivery <34 weeks but no effect on maternal or fetal outcomes. | Trial quality was not discussed |
| ATC 2009 [3]      | 22 trials, 6 primary prevention, 16 secondary prevention | 95,000 participants in primary prevention, 17,000 participants in secondary prevention trials | Risk of cardiovascular events, stroke, coronary events and death | Primary prevention with aspirin therapy results showed significant reduction in serious vascular events, non-fatal MI but not stroke or vascular mortality. Secondary prevention with aspirin significantly reduced serious vascular events, stroke and coronary events. Significant increase in major extracranial bleeds. | Trial quality was not discussed |
| Berger 2009 [57]  | 18 trials         | 5,269 participants; 2,823 aspirin group, 2,446 control group | Risk of cardiovascular events, stroke, coronary events, death and bleeding | Aspirin therapy significantly reduced incidence of non-fatal stroke but not all-cause mortality or MI. | Quality was assessed in 12 trials, high quality (Jadad 4–5) in 6 trials and low quality (Jadad 1–3) in 6 trials |
| Study                        | No. of trials | Participants | Risk of Outcomes                                      | Aspirin Therapy                                                   | Quality of trials                                                                 |
|------------------------------|---------------|--------------|-------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Bujold 2009 [59]             | 9 trials      | 1,317 women  | Risk of pre-eclampsia and pregnancy outcomes          | Aspirin therapy before <16 weeks was associated with reduced pre-eclampsia, severe preeclampsia and gestational hypertension. | Mixed quality of trials as 5/9 were double-blind, 6/9 used ITT and most had <6% loss to follow up |
| Cole 2009 [60]               | 4 trials      | 2,967 participants; 1,289 control, 1,678 aspirin | Risk of adenomas and adverse events                    | Aspirin therapy significantly reduced both adenomas and advanced lesions compared to placebo. | One trial was small and had many drop outs and there was no formal quality assessment |
| De Berardis 2009 [56]        | 6 trials      | 10117 participants | Risk of cardiovascular events, death and adverse events | Aspirin therapy in diabetes patient was associated with no significant reduction in cardiovascular events, cardiovascular mortality or overall mortality. | Quality was suboptimal in some studies, 3/6 had adequate allocation concealment, all studies were adequately blinded and 5/6 used ITT principles |
| Kraspoulos 2008 [13]        | 20 studies; 1 trial, 19 cohort studies | 2,930 participants | Risk of cardiovascular events, stroke, coronary events, death and vascular interventions | Among aspirin resistant patient there is significantly increased risk of cardiovascular event, death and acute coronary syndrome. | Quality of trials was high in 17/20 trials and remaining trials lacked information on quality |
| Lewis 2007 [63]              | 6 cohorts studies, 4 included aspirin | 1,373 participants | Risk of complications in surgery                      | Aspirin therapy was associated with statistically significant increase in complications. | All studies had limitations and potential biases due to observational designs |
| Mangiapanne 2008 [61]       | 10 cohort studies | 236,655 participants | Risk of breast cancer                                 | Aspirin therapy was associated with statistically significant reduction in breast cancer. | Quality was not discussed |

MI = myocardial infarction; ITT = intention to treat analysis
Figure 1. Flow diagram of selection of meta-analysis included in review.

Table 2. Number Needed to Treat for Key Outcomes in Meta-Analyses of Aspirin versus Control.

| Application of aspirin                                      | Risk of event (95% confidence interval) | Treated event rate | Control event rate | Number needed to treat               |
|-------------------------------------------------------------|-----------------------------------------|--------------------|--------------------|--------------------------------------|
| Primary and secondary prevention of cardiovascular disease   |                                         |                    |                    |                                      |
| Primary prevention of non-fatal MI                          | RR 0.77 (0.67–0.89)                     | 0.18% per year     | 0.23% per year     | 1891 (NNTB 1318–3953) per year       |
| Secondary prevention of non-fatal MI                         | RR 0.69 (0.60–0.80)                     | 6.7% per year      | 8.2% per year      | 40 (NNTB 31–61) per year             |
| Primary prevention of stroke                                | RR 0.95 (0.85–1.06)                     | 0.20% per year     | 0.21% per year     | No significant benefit               |
| Secondary prevention of stroke                               | RR 0.81 (0.71–0.92)                     | 2.08% per year     | 2.54% per year     | 208 (NNTB 136–493) per year          |
| Major GI and extracranial bleeds in primary prevention       | RR 1.54 (1.30–1.82)                     | 0.10% per year     | 0.08% per year     | 2315 (NNTH 1525–4167) per year       |
| Major GI and extracranial bleeds in secondary prevention     | RR 2.69 (1.25–5.76)                     | 0.17% per year     | 0.07% per year     | 846 (NNTH 301–5715) per year         |
### Table 2. Cont.

| Patients with peripheral vascular disease | RR 0.88 (0.76–1.04) | 8.9% (from 10 days to 6.7 years) | 11.0% (from 10 days to 6.7 years) | No significant benefit |
|------------------------------------------|----------------------|----------------------------------|----------------------------------|------------------------|
| Major cardiovascular events              | RR 0.66 (0.47–0.94)  | 2.1% (from 10 days to 6.7 years) | 3.1% (from 10 days to 6.7 years) | 95 (NNTB 61–538) (from 10 days to 6.7 years) |
| Nonfatal stroke                           |                      |                                  |                                  |                        |

| Patients with diabetes                    | RR 0.90 (0.81–1.00)  | 12.5% (from 3–10 years)          | 13.7% (from 3–10 years)          | No significant benefit |
|------------------------------------------|----------------------|----------------------------------|----------------------------------|------------------------|
| Major cardiovascular events              |                      |                                  |                                  |                        |

| Patients with pre-eclampsia              | RR 0.90 (0.84–0.97)  | 7.9% during course of pregnancy  | 8.7% during course of pregnancy  | 115 (NNTB 72–384) during course of pregnancy |
|------------------------------------------|----------------------|----------------------------------|----------------------------------|-----------------------------------------------|

| Patients with colorectal adenoma         | RR 0.83 (0.72–0.96)  | 32.9% over 33 months             | 36.7% over 33 months             | 17 (NNTB 10–69) over 33 months                |
|------------------------------------------|----------------------|----------------------------------|----------------------------------|-----------------------------------------------|
| Prevention of any adenoma                | RR 0.72 (0.57–0.90)  | 8.7% over 33 months              | 11.9% over 33 months             | 31 (NNTB 20–85) over 33 months                |
| Prevention of advanced adenomas          |                      |                                  |                                  |                                                |

### 3.1. Aspirin in cardiovascular disease

Four meta-analyses reviewed the use of aspirin therapy for cardiovascular prevention in different patient populations. One paper considered the benefits of aspirin in both primary and secondary prevention of vascular diseases [3] while the other meta-analyses reviewed the role of aspirin in other patient groups such as patients with diabetes, [56] peripheral vascular disease [57] and aspirin resistance [13].

The largest meta-analysis evaluated a variety of cardiovascular and haemorrhagic events in six primary prevention trials and 16 secondary prevention trials [3]. All the studies included in the meta-analysis were randomized controlled trials. For primary prevention, aspirin therapy was associated with a significant risk reduction in non-fatal MI (RR 0.77 95% CI 0.67–0.89), absolute risk 0.18% with aspirin versus 0.23% with control). However, there was no statistically significant risk reduction for important outcomes such as death from coronary heart disease (RR 0.95 95% CI 0.78–1.15, absolute risk 0.11% with aspirin versus 0.12% with control) or stroke (RR 1.21, 95% CI 0.84–1.74, absolute risk 0.20% with aspirin versus 0.21% with control). On the other hand in secondary prevention there is a significant reduction in most cardiovascular outcomes encompassing non-fatal MI (RR 0.69 95% CI 0.60–0.80), death from coronary heart disease (RR 0.87 95% CI 0.78–0.98) and stroke (RR 0.81 95% CI 0.71–0.92). The absolute risk for events in secondary prevention trial of
aspirin compared to control was 6.7% versus 8.2% for serious vascular events, 2.08% versus 2.54% for total stroke and 4.3% versus 5.3% for coronary events. This meta-analysis also showed that aspirin therapy significantly increased major extracranial bleeds (RR 2.69 95% CI 1.25–5.76) and was associated with a trend towards more haemorrhagic strokes (RR 1.67 95% CI 0.97–2.90). In view of the potentially serious harm, the authors conclude that there is still uncertainty regarding the net value of aspirin therapy in primary prevention, and aspirin use in such patients may not be warranted due to their low absolute risk reduction with high NNTs.

Another meta-analysis reviewed the subgroup of patients with peripheral artery disease [57] and included 18 prospective randomized trials with 5,269 participants. The pooled results of any aspirin therapy compared to control group showed no statistical difference for major cardiac events (RR 0.88, 95% CI 0.76–1.04), non-fatal MI (RR 1.04 95% CI 0.78–1.39, absolute risk 3.3% with aspirin versus 3.6% with control), or cardiovascular death (RR 0.94 95% CI 0.74–1.19, absolute risk 4.6% with aspirin versus 5.2% control group). The only apparent benefit seemed to be a significant reduction in non-fatal stroke with aspirin therapy (alone or combined with other antiplatelet agents) compared to controls (RR 0.66 95% CI 0.47–0.94, absolute risk 1.8% with aspirin versus 3.1% with control). Treatment with aspirin monotherapy showed similar results with statistical significance for non-fatal stroke (RR 0.64, 95% CI 0.42–0.99, absolute risk 2.1% with aspirin versus 3.4% with control) but no significant benefit for myocardial infarction (RR 0.88 95% CI 0.36–2.14, absolute risk 3.9% with aspirin versus 4.5% with control), cardiovascular death (RR 1.15 95% 0.78–1.68, absolute risk 3.6% with aspirin versus 3.3% with control), and overall mortality (RR 0.96 95% CI 0.75–1.22, absolute risk 7.5% with aspirin versus 7.9% with control). The authors conclude that aspirin does not have significant benefit on cardiovascular events overall compared to placebo in patients with peripheral vascular disease, other than for the outcome of nonfatal stroke. This challenges the common practice of using aspirin in subgroups of patients with peripheral arterial disease who do not have any other significant cardiovascular pathology.

Cardiovascular morbidity and mortality are major concerns in patients with diabetes mellitus and a variety of treatment options have been proposed. The impact of aspirin in patients with diabetes was reviewed in a meta-analysis that included six randomized controlled trials and 10,117 participants [56]. The pooled analysis reported no significant difference between aspirin and control group for important outcomes such as myocardial infarction (RR 0.86 95% CI 0.61–1.21, absolute risk 12.5% with aspirin versus 13.7% with control), stroke (RR 0.83 95% CI 0.60–1.14, absolute risk 3.8% with aspirin versus 4.2% with control), and all cause mortality (RR 0.93 95% CI 0.82–1.05, absolute risk 11.5% with aspirin versus 12.3% with control). There were trends towards increased adverse effects such as any bleeding (RR 2.50 95% CI 0.76–8.21), gastrointestinal bleeding (RR 2.11 95% CI 0.64–6.95) and gastrointestinal symptoms (RR 5.09 95% CI 0.08–314.39). However this review was limited because of heterogeneity in the analysis which could not be fully explored due to limited data. The authors concluded that aspirin cannot be routinely recommended for primary prevention of cardiovascular events in patients with diabetes mellitus, and further research need to be conducted.

The fourth meta-analysis reviewed aspirin resistance and risk of cardiovascular mortality in 20 studies of 2,930 participants [13]. Only one study in the meta-analysis a prospective randomized trial and the remaining 19 were cohort studies. This meta-analysis found that there was significant increase in risk of death (OR 5.99 95% CI 2.28–15.72), acute coronary syndrome (OR 4.06 95% CI 2.96–5.56),
and cerebrovascular events (OR 3.85 95% CI 3.08–4.80) among patients with laboratory defined “aspirin resistance”. This study had the advantage that 17 of the 20 trials had low risk of bias. However, amongst the limitations were the inability to evaluate the patients’ comorbidities, uncertainty as to which platelet function test is most reliable, and difficulty in ruling out treatment non-compliance as a cause of “aspirin resistance”. This study concludes that aspirin resistance adversely affects clinical outcomes but doctors should consider the evidence with caution as the overall benefit of aspirin is well proven in large trials. There is also little evidence on the best management strategies for patients who are found to be aspirin resistant on laboratory testing, nor do we know if these patients have similar or lower risks of haemorrhagic adverse effects.

3.2. Aspirin in obstetrics

Two meta-analyses reviewed the use of aspirin therapy in the prevention of pre-eclampsia and other outcomes of pregnancy [58,59]. One review reported the results from an individual patient data meta-analysis of 31 randomized control trials that included 32,217 women and 32,819 babies [58]. Antiplatelet agents were associated with a significant reduction of obstetric outcomes such as pre-eclampsia (RR 0.90 95% CI 0.84–0.97, absolute risk of events 7.9% with aspirin versus 8.7% with control) and preterm birth before 34 weeks gestation (RR 0.90 95% CI 0.83–0.98, absolute risk 6.5% with aspirin versus 7.2% with control) compared to placebo. However, antiplatelet use did not seem to significantly affect the risk of certain maternal outcomes such as ante-partum haemorrhage (RR 1.02, 95% CI 0.90–1.15, absolute risk 3.8% with aspirin versus 3.7% with control), Caesarian section (RR 1.03, 95% CI 0.99–1.08, absolute risk 22.9% with aspirin versus 22% with control) and post-partum haemorrhage (RR 1.06 95% CI 1.00–1.13, absolute risk 15.3% with aspirin versus 14.5% with control). For fetal outcomes, antiplatelet use was associated with significant reductions in preterm birth <37 weeks (RR 0.93 95% CI 0.89–0.98, absolute risk 16.8% with aspirin versus 18.0% with control) and need for infant ventilation (RR 0.79 95% CI 0.67–0.95, absolute risk 5.5% with aspirin versus 6.8% with control) but this was not significant for preterm birth <28 weeks (RR 0.87 95% CI 0.75–1.02, absolute risk 1.9% with aspirin versus 2.2% with control). In this meta-analysis, the authors did not find any significant benefit in reducing fetal death (RR 0.91 95% CI 0.81–1.03) or preventing growth retardation (small for gestational age) (RR 0.90 95% CI 0.85–0.96) The authors concluded that antiplatelet agents show moderate (but consistent) reductions in risk of pre-eclampsia, and preterm birth before 34 weeks’ gestation. However, there were many other outcomes where the benefits of antiplatelet therapy were unproven.

A more recent review specifically evaluated the use of aspirin in preventing pre-eclampsia and intra-uterine growth restriction in women who are at risk of pre-eclampsia [59]. This review evaluated the results of nine randomized controlled trials with 1,317 women and looked for differences in outcomes according to the time of treatment initiation. The reviewers reported that aspirin use before 16 weeks gestation was associated with a significant reduction in pre-eclampsia (RR 0.48 95% CI 0.33–0.68, absolute risk 23.3% with aspirin versus 47.2% with control) while treatment afterwards at 17-19 weeks (RR 0.55 95% CI 0.17–1.76, absolute risk 7.7% with aspirin versus 14.0% with control) and 20 weeks and beyond (RR 0.82 95% CI 0.62–1.09, absolute risk 14.3% with aspirin versus 17.4% with control) was not significantly better than control. Compared to control, aspirin therapy initiated
before 16 weeks led to lower rates of severe preeclampsia [RR 0.38 95% CI 0.15–0.98, NNT 21 (13–50)], gestational hypertension [RR 0.61 95% CI 0.40–0.93, NNT 10 (6–50)] and intra-uterine growth restriction (RR 0.51 95% CI 0.28–0.92) but no difference in preterm birth (RR 0.93 95% CI 0.46–1.90). There was no significant difference for overall for aspirin therapy (commenced at any time) compared to control group for birth weight and gestational age at birth. This study concluded that the benefits of aspirin therapy were only observed in the subgroup of patients that were treated prior to 16 weeks gestation.

3.3. Aspirin in neoplastic conditions

The most recent review of aspirin therapy in preventing the development of colorectal adenomas was included in this review [60]. The meta-analysis included four randomized double-blind controlled trials that investigated the secondary prevention of colorectal adenoma in 1,289 participants in the placebo group and 1,678 participants in the aspirin (81–325 mg daily dose) group. Recurrence of adenoma was checked with colonoscopy, and the trials had a median follow-up of 33 months. This review reported that any dose of aspirin compared to placebo was associated with a reduced risk of adenoma (RR 0.83 95% CI 0.72–0.96, absolute risk 32.9% with aspirin versus 36.7% with control) and advanced lesions (RR 0.72 95% CI 0.57–0.90, absolute risk 8.7% with aspirin versus 11.9% with control). In terms of adverse events, the rate of death, myocardial infarction, major bleeding and new cancer diagnosis was not significantly different in both aspirin and placebo group. However, all reported cases of stroke occurred in the aspirin-treated group. This review concluded that trial data supports the use of aspirin in reducing the risk of recurrent colorectal adenomas.

One meta-analysis reviewed the use of aspirin therapy in chemoprotection of breast cancer [61]. This recent meta-analysis included 10 observational studies comprising of four cohort studies and six case control studies. There was a significant difference in reduction of breast cancer with aspirin therapy compared to control (RR 0.75 95% CI 0.64–0.88) in a random-effects meta-analysis. Stratifying for study design, the risk reduction with aspirin was greater in the case control studies (RR 0.70 95% CI 0.56–0.87) compare to cohort studies (RR 0.82 95% CI 0.73–0.92). Using two different models to study dose-response relationships, Berlin (ppw1 and dur1) and Il’yasova (ppw2 and dur2), both methods showed significant protective effect with high frequency of aspirin use (ppw1 = 0.002 and ppw2 = 0.001), but only the Il’yasova method was significant (dur1 = 0.06, dur2 = 0.04) for duration. The results of this review concluded that current evidence suggests the use of aspirin may reduce the risk of breast cancer and a dose-response relationship exists. However, the validity of the data is limited because of heterogeneity, difference in determining aspirin exposure, and risk of bias from the observational designs.

3.4. Adverse effects of aspirin in patients having surgical procedures

Two meta-analyses reviewed the haemorrhagic adverse effects of aspirin therapy in patients undergoing invasive procedures. One evaluated the use of aspirin in surgical revascularization of coronary artery disease [62] and the other reviewed the use of aspirin in cutaneous surgery [63].

One meta-analysis reviewed the risk of bleeding with pre-operative aspirin therapy [62]. This meta-analysis reviewed ten studies with 1,748 patients, with 913 patients on aspirin therapy within seven
days of surgery, and 835 patients in the control (non-aspirin exposed) group. Five trials out of the ten were randomized controlled trials while the remaining five were cohort studies. Pooling of all studies showed increased chest tube loss in the aspirin group that was significantly different from the control group (WMD = 210 mL 95% CI 87–333 mL, p < 0.01). Patients in the control group had a significantly reduced requirement for blood products such as packed red blood cell transfusion (WMD = 0.65 units/patients 95% CI 0.19–1.10 units/patient, p = 0.01) and fresh frozen plasma (WMD = 0.61 units/patient 95% CI 0.07–1.16 units/patient, p = 0.03), with a trend towards a lower requirement for platelet infusion (WMD = 0.6 units/patient 95% CI 0.04–1.24 units/patient, p = 0.06). Reexploration for rebleeding was increased in the group treated with aspirin which was significant (RR 2.32 95% CI 1.31–4.08, p < 0.01). This review concluded that patients who receive aspirin within seven days of surgery were at higher risk of blood loss, but the validity of the data was limited because many studies were of low methodological quality.

Aspirin use in dermatological surgery is associated with increased risk of post-operative bleeding but consensus about anticoagulation use is less clear. Studies have reported mixed results regarding the risk of postoperative bleeding and complications [64–67]. A meta-analysis of four prospective studies and two retrospective studies with a total of 1,373 patients reported that aspirin or NSAIDs was associated with increased risk of moderate to severe complications compared to controls (OR 2.0 95% CI, 0.97–4.13, p = 0.06). This study concluded that there is a low but significant risk of complications associated with use of anticoagulants but this risk is greater with warfarin than aspirin.

3.5. Aspirin and Gastrointestinal Harm

The effects of aspirin on gastrointestinal haemorrhage were systematically reviewed by Derry and Loke almost 10 years ago [47]. This meta-analysis found a NNT for harm of 106 over 28 months, with a fairly flat dose-response curve over the range 50 mg–325 mg, and little evidence for the purported benefits of modified release formulations. A more recent ‘best evidence’ review focusing on enteric-coated aspirin concluded that the available data showed no significant risk reduction for gastrointestinal bleeding or ulceration. [68]. Serious complications from upper gastrointestinal bleeding and perforation continues to be a major problem, with a recent systematic review showing that since 1997, mortality rates from gastrointestinal complications have continued to rise in aspirin and non-steroidal anti-inflammatory users [69].

4. Conclusions

This overview of recently published meta-analyses suggests that aspirin therapy has significant benefits in a variety of clinical settings, but there are still uncertainties that will require more research. Current evidence suggests that aspirin is beneficial for secondary prevention for cardiovascular disease, primary prevention of pre-eclampsia, and secondary prevention of colorectal adenomas. However, use of aspirin in primary prevention of cardiovascular disease, or in patients with diabetes mellitus, or in those with peripheral vascular disease is not supported by the current evidence. It is also clear that aspirin has considerable potential for harm in patients undergoing surgical procedures. The benefits of aspirin use must be weighed clinically against the risk of adverse events such as gastrointestinal and intracranial bleeding.
Acknowledgements

The authors would like to thank the journal for their invitation to submit this work.

References and Notes

1. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* **1994**, *308*, 81–106.

2. Antithromboic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* **2002**, *324*, 71–86.

3. Antithromboic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* **2009**, *373*, 1849–1860.

4. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Service Task Force Recommendation Statement. *Ann. Intern. Med.* **2009**, *150*, 396–404.

5. Pearson, T.A.; Blair, S.N.; Daniels, S.R.; Eckel, R.H.; Fair, J.M.; Fortmann, S.P.; Franklin, B.A.; Goldstein, L.B.; Greenland, P.; Grundy, S.M.; et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke 2002 update. *Circulation* **2002**, *106*, 388–391.

6. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. *Heart* **2005**, *91* (Suppl. 5), v1–v52.

7. Kuliczkowski, W.; Halawa, B.; Korolko, B.; Mazurek, W. Aspirin resistance in ischemic heart disease. *Kariol. Pol.* **2005**, *62*, 14–9.

8. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Ramirez, D.; Sabate, M.; Jimenez-Quevedo, P.; Hernandez, R.; Moreno, R.; Escaned, J.; Alfonso, F.; Bañuelos, C.; Costa, MA.; Bass, TA.; Macaya C. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. *Am. J. Cardiol.* **2006**, *97*, 38–43.

9. Hegason, C.M.; Bolin, K.M.; Hoff, J.A.; Winkler, S.R.; Manget, A.; Tortorice, K.L.; Brace, L.D. Development of aspirin resistance in persons with previous ischaemic stroke. *Stroke* **1994**, *25*, 2331–2336.

10. Kawasaki, T.; Ozeki, Y.; Igawa, T.; Kambayashi, J.-I. Increased platelet sensitivity to collagen in individuals resistant to low dose aspirin. *Stroke* **2000**, *31*, 591–596.

11. Macchi, L.; Christianes, L.; Brabant, S.; Sorel, N.; Allal, J. Mauco, G.; Brizard, A. Resistance to aspirin is associated with platelet sensitivity to adenosine diphosphate. *Thromb. Res.* **2002**, *107*, 45–49.

12. Zimmerman, N.; Wenk, A.; Kim, U.; Kienzel, P.; Weber, A.A.; Gams, E.; Schror, K.; Hohlfeld, T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. *Circulation* **2003**, *108*, 542–547.

13. Krasopoulos, G.; Brister, S.J.; Beattie, W.S.; Elliot, R.F.; Buchanan, M.R. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. *BMJ* **2008**, *336*, 195–198.
14. Patrono, C.; Garcia Rodriguez, L.A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. *N. Engl. J. Med.* 2005, 353, 2373–2383.

15. Buchanan, M.R. Biological basis and clinical implications of acetylsalicylic acid resistance. *Can. J. Cardiol.* 2006, 22, 149–151.

16. Eikelboon, J.W.; Hirsh, J.; Weitz, J.I; Johnson, M.; Yi, Q.; Yusef, S. Aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. *Circulation* 2002, 105, 1650–1655.

17. Patrono, C. Aspirin resistance: definition, mechanisms and clinical read-outs. *J. Thrombo. Haemost.* 2003, 1, 1710–1713.

18. Hennekens, C.H.; Schor, K.; Weisman, S.; Fitzgerald, G.A. Semantic complexity and aspirin resistance. *Circulation* 2004, 110, 1706–1708.

19. Cattaneo, M. Aspirin and clopidogrel: efficacy, safety, and the issues of drug resistance. *Arterioscler. Throm. Vasc. Biol.* 2004, 24, 1980–1987.

20. Duley, L.; Henderson-Smart, D.J.; Knight, M.; King, J. Antiplatelet agents for preventing pre-eclampsia and its complications. *Cochrane Database Syst. Rev.* 2003, 1, CD004659.

21. Sibai, B.M.; Cartis, S.; Thom, E.; Klebanoff, M.; McNellis, D.; Rocco, L.; Paul, R.H.; Romero, R.; Witter, F.; Rosen, M.; et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. *N. Engl. J. Med.* 1993, 329, 1213–1218.

22. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. *Lancet* 1994, 343, 619–629.

23. Golding, J. A randomised trial of low dose aspirin for primipara in pregnancy. *Br. J. Obstet. Gynaecol.* 1998, 105, 293–299.

24. Rotchell, Y.E.; Cruikshank, J.K.; Gay, M.P.; Griffiths, J.; Stewart, A.; Farrell, B.; Ayers, S.; Hennis, A.; Grant, A.; Duley, L.; Collins, R. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. *Br. J. Obstet. Gynaecol.* 1998, 105, 286–292.

25. Cartitis, S.; Sibai, B.M.; Hauth, J.; Lindheimer, M.D.; Klebanoff, M.; Thom, E.; van Dorsten, P.; Landon, M.; Paul, R.; Mi dovnik, M.; Meis, P.; Thurnau, G. Low-dose aspirin to prevent preeclampsia in women at high risk. *N. Engl. J. Med.* 1998, 338, 701–705.

26. Lindheimer, M.D. Unraveling the mysteries of preeclampsia. *Am. J. Obstet. Gynecol.* 2005, 193, 3–4.

27. Baron, J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. *Prog. Exp. Tumor Res.* 2003, 37, 1–24.

28. Flossman, E.; Rothwell, P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* 2007, 369, 1603–1613.

29. Chan, A.T.; Giovannucci, E.L.; Meyerhardt, J.A.; Schernhammer, E.S.; Curhan, G.C.; Wu, K.; Fuches, C.S. Aspirin dose and duration of use and risk of colorectal cancer in mean. *Gastroenterology* 2008, 134, 21–28.

30. Chan, A.T.; Giovannucci, E.L.; Meyerhardt, J.A.; Schernhammer, E.S.; Curhan, G.C.; Fuches, C.S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. *JAMA* 2005, 294, 914–923.
31. Sandler, R.S.; Halabi, S.; Baron, J.A.; Budinger, S.; Paskett, E.; Keresztes, R.; Petrelli, N.; Pipas, J.M.; Karp, D.D.; Loprinzi, C.L.; Steinbach, G.; Schilsky, R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *New Engl. J. Med.* 2003, 348, 883–890.

32. Logan, R.F.A.; Grainge, M.J.; Shepherd, V.C.; Armitage, N.C.; Muir, K.R. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. *Gastroenterology* 2008, 134, 29–38.

33. Benamouzig, R.; Deyra, J.; Martin, A.; Girard, B.; Jullian, E.; Piednoir, B.; Couturier, D.; Coste, T.; Little, J.; Chaussade, S. Daily soluble aspirin and prevention of colorectal adenomas recurrence: one-year results of the APACC trial. *Gastroenterology* 2003, 125, 328–336.

34. Khuder, S.A.; Mutgi, A.B. Breast cancer and NSAID use: A meta-analysis. *Br. J. Cancer* 2001, 84, 1188–1192.

35. Gonzalez-Perez, A.; Garcia Rodriguez, L.A.; Lopez-Ridaura, R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. *BMC Cancer* 2003, 3, 28.

36. Coogan, P.F.; Rao, S.R.; Rosenberg, L.; Palmer, J.R.; Strom, B.L.; Zauber, A.G.; Stolley, P.D.; Shapiro, S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. *Prev. Med.* 1999, 24, 107–109.

37. Egan, K.M.; Stampfer, M.J.; Giovannucci, E.; Rosner, B.A.; Colditz, G.A. Prospective study of regular aspirin use and the risk of breast cancer. *J. Natl. Cancer Inst.* 1996, 88, 988–993.

38. Hsiao, R.E.; Namboodiri, K.K.; Farrar, W.B. Nonsteroidal anti-inflammatory drugs and breast cancer. *Epidemiology* 1996, 7, 203–205.

39. Neugut, A.I.; Rosenberg, D.J.; Ahsan, H.; Jacobson, J.S.; Wahid, N.; Hagan, M.; Rahman, M.I.; Khan, Z.R.; Shen, L.; Pablos-Mendez, A.; Shea, S. Association between coronary heart disease and cancers of the breast, prostate and colon. *Cancer Epidemiol. Biomarkers Prev.* 1998, 7, 869–873.

40. Harris, R.E.; Kasbari, S.; Farrar, W.B. Prospective study of non-steroidal anti-inflammatory drugs and breast cancer. *Oncol. Rep.* 1999, 6, 71–73.

41. Sharpe, C.R.; Collet, J.P.; McNutt, M.; Belzile, E.; Boivin, J.F.; Hanley, J.A. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. *Br. J. Cancer* 2000, 83, 112–120.

42. Langman, M.J.; Cheng, K.K.; Gilman, E.A.; Lancashire, R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. *Br. Med. J.* 2000, 320, 1642–1646.

43. Meier, C.R.; Schmitz, S.; Jick, H. Association between acetaminophen or nonsteroidal anti-inflammatory drugs and risk of developing ovarian, breast, or colon cancer. *Pharmacotherapy* 2002, 22, 303–309.

44. Cotterchio, M.; Kreiger, N.; Sloan, M.; Steingart, A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. *Cancer Epidemiol. Biomarkers Prev.* 2001, 10, 1213–1217.

45. Johnson, T.W.; Anderson, K.E.; Lazovich, D.; Folsom A.R. Association of aspirin and nonsteroidal anti-inflammatory drugs use with breast cancer. *Cancer Epidemiol. Biomarkers Prev.* 2002, 11, 1586–1591.
46. He, J.; Whelton, P.K.; Vu, B.; Klag, M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. *JAMA* 1998, 280, 1930–1935.

47. Derry, S.; Loke, Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: a meta-analysis. *BMJ* 2000, 321, 1183–1187.

48. Bojar, R.M. *Manual of Perioperative Care in Adult Cardiac Surgery*; Blackwell: Malden, Oxford, UK, 2005.

49. Kallis, P.; Tooze, J.A.; Talbot, S.; Cowans, D.; Bevan, D.H.; Treasure, T. Pre-operative aspirin decreases platelet aggregation and increase post-operative blood loss-a prospective randomised, placebo controlled, double-blind clinical trial in 1000 patients with chronic stable angina. *Eur. J. Cardio-Thorac. Surg.* 1994, 8, 404–409.

50. Morawski, W.; Sanak, M.; Cisowski, M. Szczeklik, M.; Szczeklik, W.; Dropinski, J. Waclawczyk, T.; Ulczok, R.; Bochenek, A. Prediction of the excess perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIa polymorphism. *J. Thorac. Cardiovasc. Surg.* 2005, 130, 791–796.

51. Sethi, G.K.; Copeland, J.G.; Goldman, S.; Moritz, T.; Zadina, K.; Henderson, W.G. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. *J. Am. Coll. Cardiol.* 1990, 15, 15–20.

52. Reich, D.L.; Patel, G.C.; Vela-Cantos, F.; Bodian, C.; Lansman, S. Aspirin dose not increase homologous blood requirements in elective coronary bypass surgery. *Anesth. Analg.* 1994, 79, 4–8.

53. Veylsteke, A.; Oduro, A.; Cardan, E.; Latimer, R.D. Effect of aspirin in coronary artery bypass grafting. *J. Cardiothorac. Vasc. Anaesth.* 1997, 11, 831–834.

54. Dacey, L.J.; Munoz, J.J.; Johnson, E.R.; Leavitt, B.J.; Maloney, C.T.; Morton, J.R.; Olmstead, E.M.; Birkmeyer, J.D.; O’Connor, G.T. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. *Ann. Thorac. Surg.* 2000, 70, 1986–1990.

55. Bybee, K.A.; Powell, B.D.; Valeti, U.; Rosales, A.G.; Kopecky, S.L.; Mullany, C.; Wright, R.S. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. *Circulation* 2005, 112, 1286–1292.

56. De Berardis, G.; Sacco, M.; Strippoli, G.F.M.; Pellegrini, F.; Graziano, G.; Tognoni, G.; Nicolucci A. Aspirin for the primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. *BMJ* 2009, 339, b4531.

57. Berger, J.S.; Krantz, M.J.; Kittelson, J.M.; Hiatt, W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis or randomized trials. *JAMA* 2009, 301, 1909–1919.

58. Askie, L.M.; Duley, L.; Henderson-Smart, D.J.; Stewart, L.A. of the PAIRS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: meta-analysis of individual patient data. *Lancet* 2007, 369, 1791–1798.

59. Bujold, E.; Morency, A.-M.; Roberge, S.; Lacasse, Y.; Forest, J.-C.; Giguere, Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. *J. Obstet. Gynaecol. Can.* 2009, 31, 818–826.
60. Cole, B.F.; Logan, R.F.; Halabi, S.; Benamouzig, R.; Sandler, R.S.; Grainge, M.J.; Chaussade, S.; Baron, J.A. Aspirin for the chemoprevention of colorectal adenomas: a meta-analysis of the randomized trials. *J. Natl. Cancer. Inst.* **2009**, *101*, 256–266.

61. Mangiapane, S.; Blettner, M.; Schlattmann, P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. *Pharmacoepidemiol. Drug Saf.* **2008**, *17*, 115–124.

62. Alghamdi, A.A.; Moussa, F.; Fremes, S.E. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. *J. Card. Surg.* **2007**, *22*, 247–256.

63. Lewis, K.G.; Dufresne, Jr., R.G. A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery. *Dermatol. Surg.* **2008**, *34*, 160–165.

64. Syed, S.; Adams, B.B.; Liao, W.; Pipitone, M.; Gloster, H. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. *J. Am. Acad. Dermatol.* **2004**, *51*, 955–957.

65. Kargi, E.; Babuccu, O.; Hosnuter, M.; Babuccu, B.; Altinyazar, C. Complications of minor cutaneous surgery in patients under anticoagulant treatment. *Aesthet. Plast. Surg.* **2002**, *26*, 483–485.

66. Alcalay, J. Cutaneous surgery in patients receiving warfarin therapy. *Dermatol. Surg.* **2001**, *27*, 756–758.

67. Alam, M.; Goldberg, L.H. Serious adverse vascular events associated with perioperative interruptions of antiplatelet and anticoagulant therapy. *Dermatol. Surg.* **2002**, *28*, 992–998, discussion 998.

68. Walker, J.; Robinson, J.; Stewart J.; Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? *Interact Cardiovasc Thorac Surg.* **2007**, *6*, 519–522.

69. Straube, S.; Tramèr M.R.; Moore R.A.; Derry, S.; McQuay, H.J. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. *BMC Gastroenterol.* **2009**, *5*, 9–41.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).